Intubation in the intensive care unit (ICU) is usually an emergency. Pathophysiological
changes such as shock, respiratory failure, and metabolic acidosis in critically ill patients
can significantly increase the incidence of adverse events during intubation.
Studies have shown that esketamine has no significant effect on body metabolism, endocrine
system, liver, kidney, intestinal function and coagulation function. In terms of drug
metabolism, esketamine has high bioavailability, short half-life, faster and more comfortable
recovery of patients, and not only has the advantage of providing stable hemodynamics during
endotracheal intubation, but also counteracts the respiratory depression caused by opioids.
In addition, esketamine has antidepressant and anti-inflammatory properties. The
investigators also found that combined prophylactic and therapeutic use of esketamine could
attenuate systemic inflammation and inflammatory multi-organ injury in mice after CLP-induced
lethal sepsis.
This project aims to study the clinical effect of esketamine induction intubation and
conventional induction intubation in ICU patients.